The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy
Open accessAbstract
Purpose: Adjuvant chemotherapy for breast cancer can have adverse effects on cognition shortly after administration. Whether chemotherapy has any long-term effects on cognition is largely unknown, yet it becomes increasingly relevant because of the widespread use of chemotherapy for early-stage breast cancer and the improved survival. We investigated whether cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for breast cancer is associated with worse cognitive performance more than 20 years after treatment. Patients and Methods: This case-cohort study compared the cognitive performance of patients with breast cancer who had a history of adjuvant CMF chemotherapy treatment (six cycles; average time since treatment, 21 years; n = 196) to that of a population-based sample of women never diagnosed with cancer (n = 1,509). Participants were between 50 and 80 years of age. Exclusion criteria were ever use of adjuvant endocrine therapy, secondary malignancy, recurrence, and/or metastasis. Results: The women exposed to chemotherapy performed significantly worse than the reference group on cognitive tests of immediate (P = .015) and delayed verbal memory (P = .002), processing speed (P < .001), executive functioning (P = .013), and psychomotor speed (P = .001). They experienced fewer symptoms of depression (P < .001), yet had significantly more memory complaints on two of three measures that could not be explained by cognitive test performance. Conclusion: Survivors of breast cancer treated with adjuvant CMF chemotherapy more than 20 years ago perform worse, on average, than random population controls on neuropsychological tests. The pattern of cognitive problems is largely similar to that observed in patients shortly after cessation of chemotherapy. This study suggests that cognitive deficits following breast cancer diagnosis and subsequent CMF chemotherapy can be long lasting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Tabachnick, B. G., & Fidell, L. S. (1983) · Cited by 80,032
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267
On the generalized distance in statistics
Mahalanobis, P. C. (1936) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 6,068
The Mini‐Mental State Examination: A Comprehensive Review
Tombaugh, T. N., & McIntyre, N. J. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb01992.x · Cited by 5,152
On the meaning and use of kurtosis.
DeCarlo, L. T. (1997) · Psychological Methods · doi:10.1037//1082-989x.2.3.292 · Cited by 1,755
The Rotterdam Study: objectives and design update
Hofman, A., Breteler, M. M. B., van Duijn, C. M., Krestin, G. P., Pols, H. A., Stricker, B. H. C., Tiemeier, H., Uitterlinden, A. G., Vingerling, J. R., & Witteman, J. C. M. (2007) · European Journal of Epidemiology · doi:10.1007/s10654-007-9199-x · Cited by 1,395
Self-citationThe Purdue Pegboard: norms and studies of reliability and validity.
Tiffin, J., & Asher, E. J. (1948) · Journal of Applied Psychology · doi:10.1037/h0061266 · Cited by 1,246
Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70294-1 · Cited by 998
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Prevalence, mechanisms, and management of cancer-related cognitive impairment
Janelsins, M. C., Kesler, S. R., Ahles, T. A., & Morrow, G. R. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.864260 · Cited by 745
Cancer- and Cancer Treatment–Associated Cognitive Change: An Update on the State of the Science
Ahles, T. A., Root, J. C., & Ryan, E. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0116 · Cited by 704
Wefel, J. S., Kesler, S. R., Noll, K. R., & Schagen, S. B. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21258 · Cited by 532
Self-citationCarreira, H., Williams, R., Müller, M., Harewood, R., Stanway, S., & Bhaskaran, K. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy177 · Cited by 416
Chemotherapy-Related Cognitive Dysfunction
Wefel, J. S., & Schagen, S. B. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0264-9 · Cited by 398
Self-citationCognitive Effects of Cancer and Cancer Treatments
Ahles, T. A., & Root, J. C. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084903 · Cited by 367
Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment
Geraghty, A. C., Gibson, E. M., Ghanem, R. A., Greene, J. J., Ocampo, A., Goldstein, A. K., Ni, L., Yang, T., Marton, R. M., Paşca, S. P., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.04.032 · Cited by 288
Zimmermann, S., Dziadziuszko, R., & Peters, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.005 · Cited by 147
From the Bottom-Up: Chemotherapy and Gut-Brain Axis Dysregulation
Bajic, J. E., Johnston, I. N., Howarth, G. S., & Hutchinson, M. R. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00104 · Cited by 100
Recovery from chemotherapy-induced white matter changes in young breast cancer survivors?
Billiet, T., Emsell, L., Vandenbulcke, M., Peeters, R., Christiaens, D., Leemans, A., Van Hecke, W., Smeets, A., Amant, F., Sunaert, S., et al. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9665-8 · Cited by 81
The Effect of Systemic Chemotherapy on Neurogenesis, Plasticity and Memory
Wigmore, P. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_235 · Cited by 66
Circadian disruption and cancer- and treatment-related symptoms
Amidi, A., & Wu, L. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1009064 · Cited by 59
Park, J.-H., Jung, Y. S., Jung, Y.-M., & Bae, S. H. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-018-4546-x · Cited by 43
Association of functional dorsal attention network alterations with breast cancer and chemotherapy
Shen, C.-Y., Chen, V. C.-H., Yeh, D.-C., Huang, S.-L., Zhang, X.-R., Chai, J.-W., Huang, Y.-H., Chou, M.-C., & Weng, J.-C. (2019) · Scientific Reports · doi:10.1038/s41598-018-36380-6 · Cited by 34
Effects of Yoga-Based Interventions on Cancer-Associated Cognitive Decline: a Systematic Review
Baydoun, M., Oberoi, D., Flynn, M., Moran, C., McLennan, A., Piedalue, K.-A. L., & Carlson, L. E. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00960-5 · Cited by 31
Garland, S. N., Tulk, J., Savard, J., Rash, J. A., Browne, S., Urquhart, R., Seal, M., Thoms, J., & Laing, K. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02330 · Cited by 29
Feng, L. R., Espina, A., & Saligan, L. N. (2018) · Oncology · doi:10.1159/000487081 · Cited by 24
Haller, O. J., Semendric, I., George, R. P., Collins-Praino, L. E., & Whittaker, A. L. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105120 · Cited by 13
Metadata
- Authors
- Koppelmans, V., Breteler, M. M. B., Boogerd, W., Seynaeve, C., Gundy, C., & Schagen, S. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-04-01
- Volume
- 30
- Issue
- 10
- Pages
- 1080-1086
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168711831
- Cited by
- 556
- References
- 74
- FWCI
- 26.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.